Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,002
  • Shares Outstanding, K 57,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,820 K
  • 36-Month Beta -0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.97 +9.28%
on 10/11/18
1.26 -15.87%
on 10/08/18
-0.15 (-12.40%)
since 09/14/18
3-Month
0.47 +125.53%
on 08/07/18
3.00 -64.67%
on 07/16/18
-1.82 (-63.19%)
since 07/13/18
52-Week
0.47 +125.53%
on 08/07/18
3.30 -67.88%
on 06/20/18
-0.57 (-34.97%)
since 10/13/17

Most Recent Stories

More News
Bellerophon Provides Update on INOpulse(R) Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided an update on the Company's ongoing Phase 2b randomized, double-blind,...

BLPH : 1.06 (-2.75%)
Moving Average Crossover Alert: Bellerophon Therapeutics (BLPH)

Bellerophon Therapeutics, Inc. (BLPH) could be a stock to avoid from a technical perspective

BLPH : 1.06 (-2.75%)
Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse(R) for Treatment of Pulmonary Arterial Hypertension

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that the Data Monitoring Committee (DMC) has completed its pre-specified...

BLPH : 1.06 (-2.75%)
Bellerophon Therapeutics: 2Q Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Wednesday reported a loss of $11.5 million in its second quarter.

BLPH : 1.06 (-2.75%)
Bellerophon to Present Positive Results from Phase 2 Study of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it will present the previously reported top-line results from...

BLPH : 1.06 (-2.75%)
Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter...

BLPH : 1.06 (-2.75%)
Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease

Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that, following the receipt of minutes from a recent meeting with...

BLPH : 1.06 (-2.75%)
Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher

Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

EXAS : 65.77 (-2.16%)
BLPH : 1.06 (-2.75%)
Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%

Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

BLPH : 1.06 (-2.75%)
ALXN : 121.49 (-0.37%)
Pick 3 Biotech Money-Spinning Bets Amid Market Instability

The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.

OMED : 1.91 (-4.02%)
NVAX : 1.95 (-1.02%)
BLPH : 1.06 (-2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade BLPH with:

Business Summary

Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton,...

See More

Key Turning Points

2nd Resistance Point 1.19
1st Resistance Point 1.12
Last Price 1.06
1st Support Level 1.02
2nd Support Level 0.99

See More

52-Week High 3.30
Fibonacci 61.8% 2.22
Fibonacci 50% 1.88
Fibonacci 38.2% 1.55
Last Price 1.06
52-Week Low 0.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar